Search research articles
Contact Us
Filters
Showing results (241-250 of 471) with videos related to
Page
of 48
Sort By:
European Journal of Heart Failure
|
June 22, 2007
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
Marco Metra, Christian Torp-Pedersen, John G F Cleland, et al.
Diabetes Care
|
February 7, 2009
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program
David Preiss, Sofia Zetterstrand, John J V McMurray, et al.
European Journal of Heart Failure
|
January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
Jennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
Journal of Medical Internet Research
|
December 13, 2021
Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial
Lilas Ali, Sara Wallström, Andreas Fors, et al.
JAMA
|
March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.
European Journal of Heart Failure
|
February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
R A P Weir, John J V McMurray, Margareta Puu, et al.
Kardiologia Polska
|
September 2, 2005
[Diagnosis and treatment of acute heart failure. Guidelines of the European Society of Cardiology]
Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology
|
May 21, 2005
[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]
Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
Clinical Chemistry
|
March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial
Jacob A Udell, David A Morrow, Eugene Braunwald, et al.
JAMA Cardiology
|
November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial
Akshay S Desai, Orly Vardeny, Brian Claggett, et al.
Page
of 48
Search research articles
Search
Showing results (241-250 of 471) with videos related to
Sort By:
Page
of 48
European Journal of Heart Failure
|
June 22, 2007
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
Marco Metra, Christian Torp-Pedersen, John G F Cleland, et al.
Diabetes Care
|
February 7, 2009
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program
David Preiss, Sofia Zetterstrand, John J V McMurray, et al.
European Journal of Heart Failure
|
January 24, 2014
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
Jennifer K Rogers, Stuart J Pocock, John J V McMurray, et al.
Journal of Medical Internet Research
|
December 13, 2021
Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial
Lilas Ali, Sara Wallström, Andreas Fors, et al.
JAMA
|
March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials
Mihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.
European Journal of Heart Failure
|
February 5, 2008
Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
R A P Weir, John J V McMurray, Margareta Puu, et al.
Kardiologia Polska
|
September 2, 2005
[Diagnosis and treatment of acute heart failure. Guidelines of the European Society of Cardiology]
Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
Italian Heart Journal. Supplement : Official Journal of the Italian Federation of Cardiology
|
May 21, 2005
[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]
Markku S Nieminen, Michael Böhm, Martin R Cowie, et al.
Clinical Chemistry
|
March 20, 2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial
Jacob A Udell, David A Morrow, Eugene Braunwald, et al.
JAMA Cardiology
|
November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial
Akshay S Desai, Orly Vardeny, Brian Claggett, et al.
Page
of 48